FindTrial
Sign In

Exploration of pharmacokinetic/pharmacodynamic biomarkers of donepezil and its new targets

Exploration of pharmacokinetic/pharmacodynamic biomarkers of donepezil and its new targets

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018207
Enrollment
Unknown
Registered
2018-09-05
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Case series:study group&control

Sponsors

Shanghai Sixth People's hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) HanChinese; (2) diagnosis of mild to moderate AD; and (3) adminis-tration of a stable daily dose of DNP for at least 3 months.

Exclusion criteria

Exclusion criteria: (1) non-AD dementia; and (2) administration of DNP in combination with other drugs thatare extensively metabolized by CYP2D6 or with other cognition-improving drugs.

Design outcomes

Primary

MeasureTime frame
PD genes;—

Countries

China

Contacts

Public ContactLu Jin

Shanghai Jiao Tong University affiliated sixth People's hospital

lujinsysu@hotmail.com+86 15026990219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026